Milestones & Awards – Lee's Pharmaceutical

About Us

Milestones & Awards

Milestones & Awards

2019
  • Successfully raised approximately US$50 million through the private placement of series A preferred shares of China Ophthalmology Focus Limited in May 2019
  • Formation of Lee’s Pharmaceutical Taiwan Limited, registered and operated in Taiwan


  • Official launch of Sancuso® in China


  • Official launch of Rasilez® in China


  • Official launch of VSL#3® in China


  • Honoured with “Most Innovative Small and Medium-sized Pharmaceutical Enterprises Award in the Asia Pacific Region 2019” by Clarivate Analytics


  • Honoured with “Most Growing Award” at “China Enterprise Excellence Awards Ceremony 2019”


  • Honoured with “2019 China 2nd Future Unicorn Competition Top 10 in China”


2018
  • Completed the merger of CVie Therapeutics Limited with Windtree Therapeutics, Inc. in December 2018
  • Honoured with “The Top 50 of Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area”


  • Honoured with “World Outstanding Chinese Award – Dr. Benjamin Li” by World Chinese Business Investment Foundation


2017
  • Official launch of Mictonorm® in China


  • Establishment of China Ophthalmology Focus Limited
  • Completed the acquisition of majority of shares in Windtree Therapeutics, Inc. at a consideration of US$10 million in November 2017
  • Successfully carried out the reorganization of CVie Therapeutics Company Limited into two companies: CVie Therapeutics Limited for Taiwan business and CVie Therapeutics Company Limited for China business
  • Successfully raised approximately US$7.5 million through the private placement of series A preferred shares of CVie Therapeutics Limited in May 2017
  • Honoured with “Best Listed Companies Category 2017” by Forbes


2015
  • Successfully raised approximately HK$383 million through the placement of new shares of the Company in April 2015
  • Formation of Lee’s Healthcare Industry Fund L.P. with a maximum fund size of US$20.2 million in August 2015
  • Inclusion to MSCI China Indexes
  • Inclusion to various Hang Seng Family of Indexes
  • Formation of Zhaoke Pharmaceutical (Guangzhou) Company Limited, registered and operated in Nansha District, Guangzhou, China


  • Establishment of Guangzhou Zhaokang Hospital Company Limited and acquisition of the land parcel with a total site area of approximately 36,656 m2 and with a total planned gross floor area of approximately 65,981m2 specifically for medical and sanitary use in Nansha District, Guangzhou, China in September 2015


  • Honoured with “Asia’s 200 Best Under a Billion” 2015 by Forbes


  • Honoured with “EY Entrepreneur of The Year 2015 China” by EY


2014
  • Official launch of Remodulin® in China


  • Formation of China Oncology Focus Limited with the management of the Company
2013
  • Official launch of Oral L-Carnitine® in China


  • Successfully raised approximately US$3 million through the private placement of series A-2 preferred shares of CVie Therapeutics Company Limited in March 2013
  • Successfully raised approximately US$10 million through the private placement of series B preferred shares of CVie Therapeutics Company Limited in August 2013
  • Honoured with “Asia’s 200 Best Under a Billion” 2013 by Forbes


2012
  • Official launch of Zanidi in China


  • Successfully raised approximately HK$152 million through the placement of new shares of the Company to GL Trade Investment Limited in May 2012
  • Establishment of China Cardiovascular Focus Limited and CVie Therapeutics Company Limited
  • Successfully raised approximately US$4 million through the private placement of series A-1 preferred shares of CVie Therapeutics Company Limited in July 2012
  • Honoured with“Technology Achievement Award 2012” by Hong Kong Awards for Industries


  • Honoured with “Asia’s 200 Best Under a Billion” 2012 by Forbes


2011
  • Establishment of Guangzhou Zhaoke Lianfa Pharmaceutical Limited
  • Honoured with “Asia’s 200 Best Under a Billion” 2011 by Forbes


  • Honoured with “500 Best in Asia Pacific 2011” by Deloitte


2010
  • Successfully raised approximately HK$40 million through the placement of new shares of the Company to an investor in October 2010
  • Successfully transfer of listing from GEM to Main Board of the Stock Exchange of Hong Kong Limited (Stock code: 950) on 14 May 2010


  • Establishment of Powder Pharmaceuticals, Incorporated


  • Honoured with “500 Best in Asia Pacific 2010” by Deloitte


  • Honoured with “Hong Kong Outstanding Enterprises 2010” by Economic Digest


2009
  • Successfully raised approximately HK$19 million through the placement of new shares of the Company to an investor in August 2009
2008
  • Official launch of Eyprotor® in China


2006
  • Official launch of Slounase® in China


2005
  • Completed the acquisition of the interests in Zhaoke Pharmaceutical (Hefei) Company Limited from the PRC partner and became a wholly owned subsidiary of the Group
2004
  • Successfully raised approximately HK$24 million through the placement of new shares and unlisted warrants of the Company to an investor in August 2004
2003
  • Official launch of Carnitene® in China


2002
  • Lee’s Pharmaceutical Holdings Limited announced listing of Initial Public Offering of shares on the Growth Enterprise Market (“GEM”) of the Stock Exchange of Hong Kong Limited and the shares commenced trading on 15 July 2002


2001
  • Official launch of Yallaferon® in China


1998
  • Official launch of Livaracine® in China
1997
  • Official launch of Delibrase® in China
1994
  • Establishment of the Group
  • Formation of Zhaoke Pharmaceutical (Hefei) Company Limited with a PRC partner, registered and operated in Hefei City, Anhui Province, China